ストックスクリーナーアプリを入手
1.00
6.26%
0.0589
アフターアワーズ：
.99
-0.01
-1.00%
Tempest Therapeutics Inc (TPST) 最新ニュース
TPST stock touches 52-week low at $0.91 amid market challenges - Investing.com UK
Take off with Tempest Therapeutics Inc (TPST): Get ready for trading - SETE News
Market Momentum: Tempest Therapeutics Inc (TPST) Registers a 4.39 Increase, Closing at 1.07 - The Dwinnex
TPST stock touches 52-week low at $0.92 amid market challenges By Investing.com - Investing.com South Africa
Tempest Therapeutics Inc (TPST) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Tempest Therapeutics maintains stock target, sector outperform rating - Investing.com
Tempest Therapeutics maintains stock target, sector outperform rating By Investing.com - Investing.com South Africa
TPST stock touches 52-week low at $0.92 amid market challenges - Investing.com
Was Tempest Therapeutics Inc (TPST)’s session last reading good? - US Post News
Tempest Therapeutics Inc [TPST] Stock trading around $1.10 per share: What’s Next? - The DBT News
Tempest Therapeutics Inc [NASDAQ: TPST] Sees Decrease in Stock Value - Knox Daily
Tempest Therapeutics shares retain Buy rating post Roche deal - Investing.com
Market Momentum: Tempest Therapeutics Inc (TPST) Registers a -18.52 Decrease, Closing at 1.10 - The Dwinnex
Tempest Therapeutics Inc (TPST) Stock: A Year of Market Fluctuations - The InvestChronicle
TPST’s price-to-free cash flow ratio: What it means for investors - US Post News
Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study - XM
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday? - Yahoo Finance
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Tempest Therapeutics to Advance Liver Cancer Drug to Phase 3 Trial with Roche; Shares Jump Pre-Bell - Marketscreener.com
Tempest stock gains on Roche collaboration (NASDAQ:TPST) - Seeking Alpha
Tempest Therapeutics partners with Roche on cancer trial - Investing.com
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial - ForexTV.com
Tempest Therapeutics, Inc Enters into Master Clinical Supply Agreement with F. Hoffmann-La Roche Ltd. to Which Roche Will Supply Roche?S Atezolizumab - Marketscreener.com
Tempest Extends Limited Duration Stockholder Rights Plan - GlobeNewswire
Tempest Announces Agreement with Roche to Support - GlobeNewswire
Healthy Upside Potential: Tempest Therapeutics Inc (TPST) - SETE News
TPST Shares Experience Surge in Value - Knox Daily
How to interpret Tempest Therapeutics Inc (TPST)’s stock chart patterns - US Post News
Scotiabank initates Tempest Therapeutics Inc (TPST) rating to a Sector outperform - Knox Daily
Quarterly Metrics: Quick and Current Ratios for Tempest Therapeutics Inc (TPST) - The Dwinnex
Sigourney Weaver to star in Jamie Lloyd's 'The Tempest' this fall - LondonTheatre.co.uk
A Closer Look at Tempus AI Inc. (TEM) Stock Gains - The InvestChronicle
The Tempest cast announced to join Sigourney Weaver at the Theatre Royal Drury Lane in London - WestEndTheatre.com
See Who's Joining Sigourney Weaver in West End The Tempest - Playbill
Davidson Kempner Capital Management LP Acquires New Shares in Tempus AI, Inc. (NASDAQ:TEM) - MarketBeat
Full Cast Announced for The Tempest at Theatre Royal Drury Lane - London Theatre 1
Gavin & Stacey star joins Sigourney Weaver in The Tempest - RadioTimes
The Tempest with Sigourney Weaver at Theatre Royal Drury Lane announces complete casting - WhatsOnStage.com
Full cast announced for Jamie Lloyd Company’s THE TEMPEST at Theatre Royal Drury Lane - West End Best Friend
Brokerages Set Tempus AI, Inc. (NASDAQ:TEM) Price Target at $45.56 - MarketBeat
Tempus AI (NASDAQ:TEM) Shares Gap Up to $50.09 - Defense World
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tempus AI (NASDAQ:TEM) Shares Down 5.3% - Defense World
Deeper Dive: Understanding Tempus AI Inc. (TEM) Through its Various Ratios - The Dwinnex
Just the Facts: Tempest Minerals begins fieldwork at Five Wheel Project - Proactive Investors UK
Tempus AI Inc. [TEM] Investment Guide: What You Need to Know - Knox Daily
Keeping an Eye on Tempest Therapeutics Inc (TPST) After Insider Trading Activity - Knox Daily
An analyst sees good growth prospects for Tempus AI Inc. (TEM) - SETE News
Tempest Further Strengthens Leadership Team with - GlobeNewswire
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs - StockTitan
Tempest Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
An Analysis of Tempest Therapeutics Inc (TPST)’s Potential Price Growth - Knox Daily
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Tempest Therapeutics Inc [TPST] Records 200-Day SMA of $3.1810 - Knox Daily
Is Tempest Therapeutics Inc (TPST) worth investing in despite its undervalued state? - US Post News
Scotiabank initates Tempest Therapeutics Inc (TPST) stock to a Sector outperform - Knox Daily
Anchoring Your Portfolio: Is TPST Stock a Safe Harbor? - The InvestChronicle
Ratios Uncovered: Breaking Down Tempest Therapeutics Inc (TPST)’s Trailing Twelve Months Metrics - The Dwinnex
You might want to take a look at Tempest Therapeutics Inc (TPST) now - SETE News
The Attractiveness of Investing In Tempest Therapeutics Inc (TPST) is Growing - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing Tempest Therapeutics Inc (TPST)’s Performance - The Dwinnex
How To Buy Tempest Therapeutics Inc. Stock Online in August 2024 - Traders Union
Should investors be concerned about Tempest Therapeutics Inc (TPST)? - US Post News
TPST’s 2023 Market Dance: Down -67.73% – Time to Invest? - The InvestChronicle
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):